《AAN指南PPT-治疗痛性糖尿病神经病.ppt》由会员分享,可在线阅读,更多相关《AAN指南PPT-治疗痛性糖尿病神经病.ppt(50页珍藏版)》请在三一文库上搜索。
1、Treatment of Painful Diabetic Neuropathy,Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,Vera Bril, MD, FRCP(C); John England, MD, FAAN; Gary M. Franklin, MD, MPH,
2、FAAN; Miroslav Backonja, MD; Jeffrey Cohen, MD, FAAN; David Del Toro, MD; Eva Feldman, MD, PhD, FAAN; Donald J. Iverson, MD, FAAN; Bruce Perkins, MD, FRCP(C), MPH; James W. Russell, MD, MS, FRPC; Douglas Zochodne, MD,If you have questions, comments, or feedback regarding this slide presentation, or
3、would like to modify the contents for presentation in a lecture, please contact ,Presentation Objectives,To present analysis of the efficacy of pharmacologic and nonpharmacologic treatments to reduce pain and improve physical function and quality of life (QOL) in patients with painful diabetic neuro
4、pathy (PDN) To present evidence-based recommendations,Overview,Background Gaps in care American Academy of Neurology (AAN) guideline process Analysis of evidence, conclusions, recommendations Recommendations for future research,Background,Diabetic sensorimotor polyneuropathy represents a diffuse sym
5、metric and length-dependent injury to peripheral nerves that has major implications for QOL, morbidity, and cost from a public health perspective.1,2 PDN affects 16% of patients with diabetes; it is frequently unreported (12.5%) and more frequently untreated (39%).3 PDN presents an ongoing managemen
6、t problem for patients, caregivers, and physicians. Many treatment options are available, and a rational approach to treating patients with PDN requires an understanding of the evidence for each intervention. This guideline addresses the efficacy of pharmacologic and nonpharmacologic treatments to r
7、educe pain and improve physical function and QOL in patients with PDN.,Background, cont.,Pharmacologic Agents: Anticonvulsants, antidepressants, opioids, antiarrhythmics, cannabinoids, aldose reductase inhibitors, protein kinase C beta inhibitors, antioxidants (-lipoic acid), transketolase activator
8、s (thiamines and allithiamines), topical medications (analgesic patches, anesthetic patches, capsaicin cream, clonidine), and others Nonpharmacologic Modalities: Infrared therapy, shoe magnets, exercise, acupuncture, external stimulation (transcutaneous electrical nerve stimulation), spinal cord sti
9、mulation, biofeedback and behavioral therapy, surgical decompression, and intrathecal baclofen,Gaps in Care,The chronic effect of drug therapies is not known (how long to treat, when or whether to withdraw treatment). There is an insufficient number of comparative studies among high-quality studies
10、(most were Class II or lower). There is no uniformity in how to measure pain, QOL, and function across the studies examined. Lack of cost effectiveness is apparent in all of the studies. Estimated numbers needed to treat are available, but numbers needed to harm are not available. The AAN classifies
11、 studies by quality of the evidence, not by cost.,Gaps in Care, cont.,Practitioners dont identify pain enough in peripheral neuropathy or diabetic neuropathy. Patients with diabetes often arent aware that nerve pain is a symptom. Most neuropathy therapies treat pain but not numbness. There is a lack
12、 of attention to PDN as a disease entity.,AAN Guideline Process,Clinical Question Evidence Conclusions Recommendations,Clinical Questions,The first step in developing guidelines is to clearly formulate questions to be answered. Questions address areas of controversy, confusion, or variation in pract
13、ice. Questions must be answerable with data from the literature. Answering the question must have the potential to improve care/patient outcomes.,Literature Search/Review,Rigorous, Comprehensive, Transparent,AAN Classification of Evidence,All studies rated Class I, II, III, or IV Five different clas
14、sification systems: Therapeutic Randomization, control, blinding Diagnostic Comparison to gold standard Prognostic Screening Causation,AAN Level of Recommendations,A = Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condit
15、ion in the specified population. B = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. C = Possibly effective, ineffective or harmful (or possibly useful/predictive or not useful/predictive) for th
16、e given condition in the specified population. U = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven. Note that recommendations can be positive or negative.,Translating Class to Recommendations,A = Requires at least two consistent Class I studies.* B =
17、Requires at least one Class I study or two consistent Class II studies. C = Requires at least one Class II study or two consistent Class III studies. U = Studies not meeting criteria for Class I through Class III.,Translating Class to Recommendations, cont.,* In exceptional cases, one convincing Cla
18、ss I study may suffice for an “A” recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome 5 and the lower limit of the confidence interval is 2).,Applying This Process to the Issue,We will now turn our attention to the guidelines.,Clinical Quest
19、ions,1. In patients with PDN, what is the efficacy of pharmacologic agents to reduce pain and improve physical function and QOL? In patients with PDN, what is the efficacy of nonpharmacologic modalities to reduce pain and improve physical function and QOL?,Methods,MEDLINE and EMBASE 1960 to August 2
20、008 Relevant, fully published, peer-reviewed articles MeSH term “diabetic neuropathies” and its text word synonyms and key words for the therapeutic interventions of interest (see published guideline for full list of terms),Methods, cont.,At least two authors reviewed each article for inclusion. Ris
21、k of bias was determined using the classification of evidence for each study (Classes IIV). Strength of practice recommendations were linked directly to levels of evidence (Levels A, B, C, and U). Conflicts of interest were disclosed.,Literature Review,Inclusion criteria: Articles dealing with PDN,
22、describing the intervention clearly, reporting study completion rates, defining the outcome measures clearly Exclusion criteria: Case reports and review papers,AAN Classification of Evidence for Therapeutic Intervention,Class I: A randomized, controlled clinical trial of the intervention of interest
23、 with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences. The following are also required: concealed allocation prim
24、ary outcome(s) clearly defined exclusion/inclusion criteria clearly defined,AAN Classification of Evidence for Therapeutic Intervention, cont.,adequate accounting for drop-outs (with at least 80% of enrolled subjects completing the study) and cross-overs with numbers sufficiently low to have minimal
25、 potential for bias. For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*: The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority. The standard
26、 treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment. (e.g. for a drug, the mode of administration, dose and dosage adjustments are similar to those previously shown to be effective). The inclusion and exclusion criter
27、ia for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment. The interpretation of the results of the study is based upon a per protocol analysis that takes into account dropouts or crosso
28、vers.,AAN Classification of Evidence for Therapeutic Intervention, cont.,Class II: A randomized controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criteria ae above or a prospective matched cohort study
29、with masked or objective outcome assessment in a representative population that meets be above. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.,AAN Classification of Evidence for Thera
30、peutic Intervention, cont.,Class III: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.* Class IV: Studi
31、es not meeting Class I, II or III criteria including consensus or expert opinion. *Note that numbers 13 in Class I, item 5 are required for Class II in equivalence trials. If any one of the three are missing, the class is automatically downgraded to Class III.,Analysis of Evidence,Question 1: In pat
32、ients with PDN, what is the efficacy of pharmacologic agents to reduce pain and improve physical function and QOL?,Conclusions/Recommendation,Conclusions: Based on consistent Class I evidence, pregabalin is established as effective in lessening the pain of PDN . Pregabalin also improves QOL and less
33、ens sleep interference, though the effect size is small. Recommendation: If clinically appropriate, pregabalin should be offered for the treatment of PDN (Level A).,Conclusions/Recommendation,Conclusions: Based on 1 Class I study, gabapentin is probably effective in lessening the pain of PDN. Based
34、on 2 Class II studies, sodium valproate is probably effective in treating PDN. Recommendation: Gabapentin and sodium valproate should be considered for the treatment of PDN (Level B).,Conclusion/Recommendation,Conclusion: There is conflicting Class III evidence for the effectiveness of topiramate in
35、 treating PDN. Recommendation: There is insufficient evidence to support or refute the use of topiramate for the treatment of PDN (Level U).,Conclusions/Recommendation,Conclusions: Lamotrigine is probably not effective in treating PDN. Based on Class II evidence, oxcarbazepine is probably not effect
36、ive in treating PDN. Based on Class III evidence, lacosamide is possibly not effective in treating PDN. The degree of pain relief afforded by anticonvulsant agents is not associated with improved physical function. Recommendation: Oxcarbazepine, lamotrigine, and lacosamide should probably not be con
37、sidered for the treatment of PDN (Level B).,Clinical Context,Although sodium valproate may be effective in treating PDN, it is potentially teratogenic and should be avoided in diabetic women of childbearing age. Due to potential adverse effects such as weight gain and potential worsening of glycemic
38、 control, this drug is unlikely to be the first treatment choice for PDN.,Conclusions/Recommendations,Conclusions: Based on 3 Class I and 5 Class II studies, the antidepressants amitriptyline, venlafaxine, and duloxetine are probably effective in lessening the pain of PDN . Venlafaxine and duloxetin
39、e also improve QOL. Venlafaxine is superior to placebo in relieving pain when added to gabapentin. Recommendations: Amitriptyline, venlafaxine, and duloxetine should be considered for the treatment of PDN (Level B). Data are insufficient to recommend one of these agents over the others. Venlafaxine
40、may be added to gabapentin for a better response (Level C).,Conclusion/Recommendation,Conclusion: There is insufficient evidence to determine whether desipramine, imipramine, fluoxetine, or the combination of nortriptyline and fluphenazine are effective for the treatment of PDN. Recommendation: Ther
41、e is insufficient evidence to support or refute the use of desipramine, imipramine, fluoxetine, or the combination of nortriptyline and fluphenazine in the treatment of PDN (Level U).,Conclusions/Recommendation,Conclusions: Based on one Class I study, dextromethorphan is probably effective in lessen
42、ing the pain of PDN and improving QOL. Based on Class II evidence, morphine sulphate, tramadol, and oxycodone controlled-release are probably effective in lessening the pain of PDN. Dextromethorphan, tramadol, and oxycodone controlled-release have moderate effect sizes, reducing pain by 27% compared
43、 with placebo. Recommendation: Dextromethorphan, morphine sulphate, tramadol, and oxycodone should be considered for the treatment of PDN (Level B). Data are insufficient to recommend one agent over the other.,Clinical Context,The use of opioids for chronic nonmalignant pain has gained credence over
44、 the last decade due to the studies reviewed in this article. Both tramadol and dextromethorphan were associated with substantial adverse events (e.g., sedation in 18% on tramadol and 58% on dextromethorphan, nausea in 23% on tramadol, and constipation in 21% on tramadol). The use of opioids can be
45、associated with the development of novel pain syndromes such as rebound headache. Chronic use of opioids leads to tolerance and frequent escalation of dose.,Conclusions/Recommendation,Conclusions: Based on Class I and Class II evidence, capsaicin cream is probably effective in lessening the pain of
46、PDN. Based on Class I evidence, isosorbide dinitrate spray is probably effective for the treatment of PDN. Recommendation: Capsaicin and isosorbide dinitrate spray should be considered for the treatment of PDN (Level B).,Conclusions/Recommendation,Conclusions: Based on Class III studies, there is in
47、sufficient evidence to determine if IV lidocaine is effective in lessening the pain of PDN. Based on Class III evidence, the Lidoderm patch is possibly effective in lessening the pain of PDN. Recommendation: The Lidoderm patch may be considered for the treatment of PDN (Level C).,Conclusions/Recomme
48、ndation,Conclusions: Based on Class I evidence, clonidine and pentoxifylline are probably not effective for the treatment of PDN. The evidence for the effectiveness of mexiletine is contradictory; however, the only Class I study of this agent indicates that mexiletine is probably ineffective for the
49、 treatment of PDN. Recommendation: Clonidine, pentoxifylline, and mexiletine should probably not be considered for the treatment of PDN (Level B).,Conclusion/Recommendation,Conclusion: There is insufficient evidence to determine whether vitamins and -lipoic acid are effective for the treatment of PDN. Recommendation: There is insufficient evidence to support or refute the usefulness of vitamins and -lipoic acid in the treatment of PDN (Level U).,Clinical Context,Although capsaicin has been effective in reducing pain in PDN clinical trial
链接地址:https://www.31doc.com/p-2099659.html